
Enliven Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ELVN | Enliven Therapeutics | 46.53 | 24.78 | 113.93% |
| Name | Price | % Change | |
|---|---|---|---|
| $46.53 | +113.93% |

Enliven Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a

As of September 30, the company had cash, cash equivalents and marketable securities totaling $884.4M, which is expected to provide cash runway into 2030. “This quarter marked an important milestone

H.C. Wainwright raised the firm’s price target on Enliven (ELVN) to $73 from $65 and keeps a Buy rating on the shares. The firm views the company’s planned ENABLE-2 trial

Enliven Therapeutics ( ($ELVN) ) has issued an announcement. On October 14, 2026, Enliven Therapeutics expanded its board from seven to eight members and appointed biopharmaceutical executive Kristine Ball as

William Blair analyst Andy Hsieh has reiterated their bullish stance on ELVN stock, giving a Buy rating yesterday. Andy Hsieh has given his Buy rating due to a combination of

Enliven (ELVN) Therapeutics announced that it has reached alignment with the U.S. FDA on the final design of the ENABLE-2 pivotal trial, a Phase 3 trial of relcobatinib in patients

Morgan Stanley initiated coverage of Enliven (ELVN) with an Overweight rating and $70 price target Enliven is a clinical-stage precision oncology company developing selective small-molecule kinase inhibitors, the analyst tells

Biotech AnaLyst Syed, along with the Biotech Research Team, discuss Vaxcyte (PCVX), ahead of VAX-31 Ph3 OPUS-1 readout this October, as well as BBIO, RCUS, CYTK, ELVN, IOVA, BIIB on

JPMorgan initiated coverage of Enliven (ELVN) with an Overweight rating and $75 price target The company’s ELVN-001 can first address second-line post-allosteric chronic myeloid leukemia patients and then expand into

Mizuho analyst Salim Syed raised the firm’s price target on Enliven (ELVN) to $73 from $62 and keeps an Outperform rating on the shares. The firm updated the company’s model
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 13, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Nov 5, 2026 | ||||
| buy | Reiterated | Oct 7, 2026 | ||||
| buy | Reiterated | Oct 6, 2026 | ||||
| buy | Initiated | Oct 5, 2026 | ||||
| buy | Initiated | Oct 1, 2026 | ||||
| buy | Reiterated | Aug 17, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 18, 2027TBA | $3.42B | $-0.44 | $0.00 | 2.65 | -27.70 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.